Median survival time was 419 days for patients with luminal-type breastcancer, 1673 days for those with HER2-type breast cancer, and 80 days forthose with triple-negative breast cancer (P < 0.01)(Fig. 2). Here, ERBB2 is linked to breast carcinoma.